Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gilead Sciences, Inc. (GILD) vs Invesco S&P 500 High Div Low Volatility ETF (SPHD) Price & Performance

Gilead Sciences, Inc.Trade
Invesco S&P 500 High Div Low Volatility ETFTrade

Price performance (Past 24H)

Key statistics

Gilead Sciences, Inc. vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? Gilead Sciences, Inc. trades at $136.2 (market cap $168.35B), while Invesco S&P 500 High Div Low Volatility ETF trades at $52.22. The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while Invesco S&P 500 High Div Low Volatility ETF pays none, and Invesco S&P 500 High Div Low Volatility ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.

GILDSPHD
Market Cap
$168.35B
Sector
Health
52-Week High
$155.80$53.55
52-Week Low
$110.56$46.96
Enterprise Value
$191.42B
Dividend Yield
2.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.

The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.

Invesco S&P 500 High Div Low Volatility ETF

SPHD trades at $52.26, down 0.29% today, with a bullish technical signal supported by moving averages. The ETF focuses on high-dividend, low-volatility S&P 500 stocks, offering monthly income. Recent news highlights investor interest in dividend and value strategies amid market volatility, with articles from Zacks and 24/7 Wall Street in August 2026 emphasizing its role in retirement portfolios.

The outlook for SPHD is stable, appealing for income-focused investors seeking lower volatility. Key opportunities include consistent dividends and defensive positioning, while risks involve interest rate sensitivity and potential underperformance in strong bull markets. Analyst sentiment is generally positive for its strategy in current conditions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD

About Invesco S&P 500 High Div Low Volatility ETF

The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.

Read more on SPHD